We are live on ! Find out more
IRWD icon

Ironwood Pharmaceuticals
IRWD

221 hedge funds and large institutions have $2.09B invested in Ironwood Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 67 increasing their positions, 78 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

34% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 29

4% more funds holding

Funds holding: 212 → 221 (+9)

5% more capital invested

Capital invested by funds: $2B → $2.09B (+$92.9M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.39% less ownership

Funds ownership: 105.03% → 104.64% (-0.39%)

14% less repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 78

68% less call options, than puts

Call options by funds: $238K | Put options by funds: $734K

Holders
221
Holders Change
+9
Holders Change %
+4.25%
% of All Funds
3.49%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
39
Increased
67
Reduced
78
Closed
29
Calls
$238K
Puts
$734K
Net Calls
-$496K
Net Calls Change
-$7.51M

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$14.1M
2
Two Sigma Investments
Two Sigma Investments
New York
+$10.2M
3
PI
Putnam Investments
Massachusetts
+$8.25M
4
RA
Royce & Associates
New York
+$7.8M
5
Two Sigma Advisers
Two Sigma Advisers
New York
+$7.14M

Top Sellers

Rank Fund Capital Flow
1
CCM
Camber Capital Management
Massachusetts
-$35M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$24.3M
3
BCM
Brown Capital Management
Maryland
-$23.3M
4
Goldman Sachs
Goldman Sachs
New York
-$7.95M
5
FP
Foundry Partners
Minnesota
-$6.51M
Name Holding Trade Value Shares
Change 		Change in
Stake
SSA
226
Schonfeld Strategic Advisors
New York
– -$469K -40,200 Closed
AA
227
ALPS Advisors
Colorado
– -$363K -31,115 Closed
PAM
228
Panagora Asset Management
Massachusetts
– -$309K -26,528 Closed
PP
229
PDT Partners
New York
– -$299K -25,675 Closed
GCM
230
Graham Capital Management
Connecticut
– -$288K -24,724 Closed
ZCM
231
Zebra Capital Management
Connecticut
– -$274K -23,536 Closed
WAM
232
Watershed Asset Management
California
– -$274K -23,535 Closed
CCIA
233
Campbell & Co Investment Adviser
Maryland
– -$219K -18,816 Closed
SWM
234
Spire Wealth Management
Virginia
– -$175K -15,051 Closed
MS
235
Maven Securities
Jersey
– -$175K -15,000 Closed
AIM
236
Aigen Investment Management
New York
– -$157K -13,458 Closed
PWPS
237
Pinnacle Wealth Planning Services
Ohio
– -$122K -10,494 Closed
SFM
238
Signet Financial Management
New Jersey
– -$31K -2,640 Closed
ACM
239
Aquatic Capital Management
Illinois
– -$9K -800 Closed
SGAM
240
Smith Group Asset Management
Texas
– -$3K -230 Closed
SCA
241
Snowden Capital Advisors
New York
– -$2K -200 Closed
AWA
242
Amplius Wealth Advisors
Pennsylvania
– -$1K -100 Closed
MPWT
243
MassMutual Private Wealth & Trust
Connecticut
– -$1K -59 Closed
SC
244
Schubert & Co
Texas
– +$34 +3 +17%
SIC
245
SJS Investment Consulting
Ohio
– +$46 +4 New
AF
246
Allworth Financial
California
– +$126 +11 +73%
QCG
247
Quadrant Capital Group
Ohio
– +$183 +16 +73%
DI
248
Disciplined Investments
Oklahoma
– +$218 +19 New
Carson Wealth (CWM LLC)
249
Carson Wealth (CWM LLC)
Nebraska
– +$344 +30 New
CTC
250
Central Trust Company
Missouri
– +$550 +48 New
6 7 8 9
10

IRWD Hedge Fund Activity: Q1 2022 in Review

221 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q1 2022, worth a combined $2.09B — up 4.6% from $2B a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new IRWD positions and 29 closed out — a net gain of 10 holders — while 67 added to existing stakes and 78 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $14.1M. The largest seller was Camber Capital Management, exiting entirely with an estimated $35M sold.

  • 221 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q1 2022, up from 212 in Q4 2021.
  • Funds reported $2.09B of Ironwood Pharmaceuticals stock for Q1 2022, up 4.6% quarter-over-quarter.
  • 39 funds opened new Ironwood Pharmaceuticals positions in Q1 2022 and 29 closed out, a net change of +10 holders.
  • The largest Ironwood Pharmaceuticals buyer in Q1 2022 was Morgan Stanley, an estimated $14.1M added.
  • The largest Ironwood Pharmaceuticals seller in Q1 2022 was Camber Capital Management, an estimated $35M sold.

Based on aggregated 13F filings for Q1 2022.